These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders. Khoshnevis M; Sebag J BioDrugs; 2015 Apr; 29(2):103-12. PubMed ID: 25812991 [TBL] [Abstract][Full Text] [Related]
10. Role of vitreous in diabetic macular edema. Gandorfer A Retina; 2012 Sep; 32 Suppl 2():S211-5. PubMed ID: 22929323 [No Abstract] [Full Text] [Related]
11. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy. Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794 [TBL] [Abstract][Full Text] [Related]
12. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Sakuma T; Tanaka M; Mizota A; Inoue J; Pakola S Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3295-9. PubMed ID: 16123432 [TBL] [Abstract][Full Text] [Related]
14. Deal watch: Alcon invests in first non-surgical therapy for common eye disorder. Crunkhorn S Nat Rev Drug Discov; 2012 Apr; 11(5):342. PubMed ID: 22543460 [No Abstract] [Full Text] [Related]
15. Molecular biology of pharmacologic vitreolysis. Sebag J Trans Am Ophthalmol Soc; 2005; 103():473-94. PubMed ID: 17057814 [TBL] [Abstract][Full Text] [Related]
16. Microplasmin: ex vivo characterization of its activity in porcine vitreous. de Smet MD; Valmaggia C; Zarranz-Ventura J; Willekens B Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):814-9. PubMed ID: 18806295 [TBL] [Abstract][Full Text] [Related]
17. [Progression of pharmacologic vitreolysis research]. Zhou H; Ye J Zhonghua Yan Ke Za Zhi; 2014 Mar; 50(3):225-9. PubMed ID: 24841819 [TBL] [Abstract][Full Text] [Related]